secwatch / observer
8-K filed March 16, 2026, 7:59 PM ET ticker CRSP CIK 0001674416
debt confidence high sentiment neutral materiality 0.70

CRISPR Therapeutics completes $600M convertible note offering due 2031

CRISPR Therapeutics AG

item 1.01item 2.03item 3.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-108333
form_type
8-K
ticker
CRSP
cik
0001674416
company_name
CRISPR Therapeutics AG
filed_at
2026-03-16T23:59:59+00:00
discovered_at
2026-05-14T18:02:35.855207+00:00
generated_at
2026-05-15T11:48:33.888073+00:00
sec_items
["1.01", "2.03", "3.02", "9.01"]
event_type
debt
sentiment
neutral
materiality_score
0.7
calibrated_materiality_score
0.7
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-108333
json_url
https://secwatch.observer/filing/0001193125-26-108333.json
markdown_url
https://secwatch.observer/filing/0001193125-26-108333.md
text_url
https://secwatch.observer/filing/0001193125-26-108333.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

446d0629ab6639aa5efc249a5ae582213f76a1ff

CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

SEC 8-K Item 2.03/2.04 confidence 0.9 SEC evidence

fbb4a778578d8899f2feae408f3919c0743e8928

CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

Filing page SEC filing

TBH

Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger

Brag House Holdings, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027

Filing page SEC filing

KNX

Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver

Knight-Swift Transportation Holdings Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031

Filing page SEC filing

PUMP

ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility

ProPetro Holding Corp. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031

Filing page SEC filing

OCGN

Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan

Ocugen, Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).

Filing page SEC filing

HR

HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032

Healthcare Realty Trust Inc May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032

Filing page SEC filing

TCPC

BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities

BlackRock TCP Capital Corp. June 1, 2026, 4:50 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

Filing page SEC filing

VVX

V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin

V2X, Inc. June 1, 2026, 4:10 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)

Comparable filing

The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-108333
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.